Targeted drug therapy specifically targets specific abnormalities in cancer cells. By preventing these abnormalities from appearing, targeted drug therapy can kill the cancer cells. Targeted therapy drugs are used to treat certain types of brain tumors. Although there are still relatively few approved targeted drugs in brain tumors, as clinical trials continue, more and more targeted drugs are showing good results in brain tumors, which means that the more likely it is that patients can be matched with targeted drugs through multigene testing.
Targeted drug therapy development services for brain tumors
Alfa Oncology identifies promising targets in early drug discovery. We develop and implement high-throughput target ID screens that characterize a wide range of analytes from small molecular fragments to biologics. We utilize non-labeled binding technologies such as bio-layer interference (BLI) and surface plasmon resonance (SPR) systems to rapidly establish high-throughput binding screens. Our services can be used to identify binding targets and accurately characterize complex formation rates, complex stability, and affinity.
Alfa Oncology focuses on the role of Tregs in immunosuppression. We can provide drug development services for Tregs targets, mainly through monoclonal antibodies targeting Tregs and small molecule antagonists targeting Tregs. For this important new immune target in brain tumors, we have also developed a relevant drug target cell screening model for the binding capacity and activity of large and small molecule drugs targeting Tregs.
EGFR is often overexpressed and out of control in brain tumors and is, therefore, a hot topic for brain tumor diagnostic and therapeutic research. Alfa Oncology provides drug development services for brain tumors targeting EGFR. We are also developing EGFR-targeting nanotechnology approaches for drug delivery, as well as antibodies targeting extracellular EGFR and potential anti-EGFR antibody-drug conjugates, to provide new avenues for brain tumor treatment.M
Alfa Oncology focuses on anti-angiogenic therapies, and we provide targeted brain tumor drug development services targeting angiogenesis, particularly VEGF, to inhibit the proliferation of brain tumors, including GBM, by inhibiting the formation of new tumors blood vessels using angiogenesis inhibitors and drugs. Taking the VEGF target as an example, we have a full range of human anti-VEGF antibodies and can provide humanized monoclonal antibodies and anti-VEGF/VEGFR fusion protein development services against VEGF.